Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Sant. Comerc
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

CFR Pharmaceuticals SA

+ Add to Watchlist

CFR:CI

207.000 CLP 0.0000.00%

As of 16:21:49 ET on 02/27/2015.

Snapshot for CFR Pharmaceuticals SA (CFR)

Open: 207.000 Day's Range: 207.000 - 207.000 Volume: 0
Previous Close: 207.000 52wk Range: 109.000 - 215.000 1-Yr Rtn: +81.58%

Stock Chart for CFR

No chart data available.
  • CFR:CI 207.000
  • 1D
  • 1M
  • 1Y
207.000
Interactive CFR Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for CFR

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) 33.5407
Relative P/E vs. IPSA -
Earnings Per Share (USD) (ttm) -0.0071
Est. EPS (USD) (12/2014) 0.0100
Est. PEG Ratio -
Market Cap (M CLP) 1,742,112.00
Shares Outstanding (M) 8,416.00
30 Day Average Volume 286,472
Price/Book (mrq) 5.8648
Price/Sale (ttm) 3.7868
Dividend Indicated Gross Yield -%
Cash Dividend (CLP) 2.5331
Dividend Ex-Date 12/04/2013
5 Year Dividend Growth -
Next Earnings Announcement 03/02/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for CFR

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for CFR

CFR Pharmaceuticals SA develops pharmaceuticals. The Company develops biopharmaceutical drugs for oncology, organ transplantation, dialysis, diabetes, autoimmune diseases, human immunodeficiency virus, epilepsy and respiratory diseases, injectables for anesthesia, cardiology and critical care, and oral contraconceptives, replacement hormone therapy and antiandrogens.

Alejandro Kostia Nicolas Weinstein CrenovichChairmanPatricio Vargas MunozChief Financial Officer
Deneb SchieleHead:Investor Relations
More Company Profile & Key Executives for CFR

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil